Neuroscience Center Pioneering Alzheimer’s, Dementia Treatments – CBS Minnesota / WCCO

May 31, 2017 11:07 PM By Liz Collin

MINNEAPOLIS (WCCO) One of the few places in the country developing new treatments for dementia and Alzheimers disease is in the Twin Cities.

And those researchers and doctors now work under one roof for the first time.

HealthPartners opened the doors to its new Neuroscience Center in St. Paul this spring.

Every detail was designed with the patient in mind.

WCCO has followed one of those patients for more than two years. Dr. Paul Quinn is in the early stages of Alzheimers disease.

Paul and Peg Quinn (credit: CBS)

He always comes across somewhat hopeful in his assessment of his condition.

I cant notice a significant difference, Paul Quinn said.

He been confronting whats called mild cognitive impairment (MCI) for the last three years.

Quinn and his wife, Peg, will soon learn the results of his annual cognitive review. They are seeing if his diagnosis has changed; if his memory disorder has fully developed into Alzheimers disease.

That news will be delivered to the Quinns for the first time inside a one-of-a-kind medical center in the Midwest, which is expected to serve 50,000 patients a year.

The $75-million, 130,000-square-feet center focuses solely on brain and spine conditions.

There are finishes to help dementia patients feel more comfortable, like large exam rooms and an open floor plan.

Locations are marked with something other than numbers, which can be hard for patients to recall.

They suggested we have two ways of remembering, so we did a color and a letter at each neighborhood, said Business Systems Supervisor Heather Engebretson.

But the biggest breakthroughs happen in the basement, where Senior Research Director William Frey is on the front lines of testing medicine.

Here we are testing a number of treatments for brain disorders, Dr. Frey said.

(credit: CBS)

One of the potential treatments is a nasal spray that injects insulin into the brain.

The things we discover here, like our nasal insulin treatment that improves memory in people with Alzheimers, is actually in human clinical trials on the third floor of this very building, Dr. Frey said.

Quinn is part of another clinical trial developed by the same team that involves taking a pill a day.

It is part of a routine that, for the most part, he still keeps up himself.

Every day we wake up and were both still there and we just keep on keeping on, Peg Quinn said.

She has noticed a significant change in her 78-year-old husband since his diagnosis. Details in stories from the past now have slight changes, like when we ask Paul about the time he met Peg in 1961.

Then this gal comes in shes got a green, stylish rain coat and she has a hat on, too, he said.

His wife says she had never heard those details before.

Subtle changes to Pauls long-term memory worry his family since his short-term memory is barely there, even when it comes to relatives names.

Half the patients with MCI develop Alzheimers disease or another form of dementia within five years of the diagnosis.

Dr. Michael Rosenbloom tells Paul that his function is good overall, since hes still able to do things like cook and drive.

You were having problems naming things, but it wasnt enough to shift things dramatically, Dr. Rosenbloom said. I think youre more or less stable with a little bit worsening. I would still call this mild cognitive impairment based on what youre telling me. I think this is not a bad result. If I were in your shoes, Id be happy to hear this.

Dr. Rosenbloom says it is those functions that determines whether or not patients like Paul have MCI or Alzheimers.

It is the question that keeps the Quinns planning for the future, yet focused on living each day.

Keep on keeping on as long as you can, Peg Quinn said.

Dr. Rosenbloom did recommend that Paul and others with memory problems use brain-training game. Many can be found online.

He also says exercise is extremely important. Studies have shown even a half hour of aerobic activity, three times a week, can be as effective as medication in some patients.

At 15 years old, Liz Collin made her broadcast debut covering a tornado that touched down in southwest Minnesota. It was her first night on the job at KWOA and KO95. Since those radio days in her hometown of Worthington, Minnesota, she's held...

Read the original post:
Neuroscience Center Pioneering Alzheimer's, Dementia Treatments - CBS Minnesota / WCCO

Performance of Eli Lilly’s Neuroscience Products in 1Q17 – Market Realist

What Drives Eli Lilly's Valuation after Its 1Q17 Earnings? PART 8 OF 9

Eli Lilly & Co.s (LLY) neuroscience products portfolio includes the drugs Cymbalta, Strattera, and Zyprexa.The chart below shows revenues for its three key neuroscience productsCymbalta, Strattera, and Zyprexasince 1Q15.

Cymbalta, an antidepressant, reported a 12% decline in its 1Q17 revenues to $174.6 million, compared to ~$198.7 million in 1Q16. The drug reported lower sales outside the US markets, specifically Europe and Canada, due to the loss of exclusivity

Cymbalta reported a 20% decline in revenues to $140.5 million from international markets, partially offset by 46% growth in the US market to $34.1 million.

Strattera, a drug for the treatment ofattention-deficit hyperactivity disorder (or ADHD), reported 4% growth in its 1Q17 revenues to $196.2 million, compared to $188.1 million for 1Q16. This growth was driven by strong performance in its US and international markets.

Zyprexa, an antipsychotic drug, reported a 31% decline in revenues to $147.5 million in 1Q17, compared to $212.8 million in 1Q16. The decline was due to the exposure to generic competition in theUS and its international markets.

For broad-based exposure to the industry, investors can consider the Vanguard Healthcare ETF (VHT), which holds 2.4% of its total assets in Eli Lilly. VHT also holds 10.0% of its total assets in Johnson & Johnson (JNJ), 2.9% of its total assets in Celgene (CELG), 2.2% of its total assets in Abbott Laboratories (ABT), and 1.7% of its total assets in Biogen (BIIB).

Read the original:
Performance of Eli Lilly's Neuroscience Products in 1Q17 - Market Realist

New Thematic Series for BMC Immunology: Cancer Immunotherapy … – BMC Blogs Network (blog)

BMC Immunology is delighted to announce the launch of a new thematic series: "Cancer Immunotherapy and Vaccines". Here, Guest Editor Francesco Pappalardo gives an introduction to the series and discusses the progress and the difficulties faced by researchers in the field.

Professor Francesco Pappalardo 31 May 2017

Pixabay

Vaccines are the most effective and cost-efficient weapons that can be used to prevent (preventive vaccines) or cure (therapeutic vaccines) diseases caused by infectious agents or cancer cells. Usually, when one thinks about the word vaccine, the first thought that comes into the mind is related to an artificial administration of a stimulus that instructs the immune system to fight against the cause of a particular pathological state (the pathogen). However, in the case of cancer vaccines, the main view, still unknown to the majority of the people not working in the field, is represented by the exploitation of the hosts immune system to treat or prevent cancer. The idea, however, dates back decades.

In the same way a traditional vaccine works, a cancer vaccine can promote the eradication of malignant cells during their initial transformation from safe to harmful cells. This eradication process, commonly referred to as immune surveillance of tumors [1], is carried out by the immune system and, most of the time, it happens without any external intervention. Tumors are the result of a particular combination of factors related to genetic and epigenetic changes that enable immortality.

In the same way a traditional vaccine works, a cancer vaccine can promote the eradication of malignant cells during their initial transformation from safe to harmful cells.

This is not a completely undetectable process: during the transformation of a normal cell into a malignant one, foreign antigens (neo-antigens or, to be more specific, onco-antigens) are created; these should render neoplastic cells visible by the immune system that can target them for elimination. Tumors cells, like every living organisms, want, nevertheless, to live. Hence, tumors try to become resistant and invisible to immune system attacks by developing multiple resistance mechanisms that include local immune evasion, induction of tolerance and systemic interference of T cell signaling. Besides, mimicking the metaphor of Darwins natural selection, immune recognition of cancer cells enforces a selective pressure on developing ones. This favors the development of less immunogenic and more apoptosis-resistant neoplastic cells, through a mechanism well known as immune editing [2].

Due to the fact that cancer cells are particularly good at evading any action from the immune system, most anti-cancer treatments are based on other means like surgery, radiation therapy, and chemotherapy. Nowadays, however, it is clear that the various arms of the immune system play an essential role in protecting humans from cancer. After unsatisfactory efforts and explicit clinical failures, the field of cancer immunotherapy has received a significant boost, thanks mainlyto the development in 2010of an autologous cellular immunotherapy, sipuleucel-T, for the treatment of prostate cancer [3] and the approval of the anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) antibody ipilimumab (2011) andanti-programmed cell death protein 1 (PD1) antibodies (2014) for the treatment of melanoma [4]. These achievements haverenovated the field and brought attention to the opportunities that immunotherapeutic approaches can offer [5,6].

The field of cancer immunotherapy has recently received a significant boost

Pixabay

There are still, however, some difficulties to be overcome when developing effective immunotherapy strategies against cancer. The general lack of understanding of the mechanisms of immunization, the role of dendritic cells, the ability of cancer to induce tolerance, and the identification of the most suitable antigens to use are just some examples of how the development of effective strategies is still problematic [7-10]. There are several biotechnological methodologies, based on both in silico and in vivo techniques, that study and suggest possible candidates for use in immunotherapies. However, they are not able, on their own, to quantify and analyze the immune system response globally. Moreover, there are now several computational techniques to predict T cell epitopes (and,to some extent, also B cell epitopes) [11,12]. Computational simulations may help in solving these issues, but these need to be integrated with the in vitro and in silico molecular analyses [13,14]. So, a complete computational/biological pipeline that allow the best integration of in silico, in vitro and in vivo methodologies may potentially boost and improve cancer immunotherapy development and effectiveness.

The aim of the thematic series is to bring together the latest advances in both biological and computational research, looking broadly at the basic biological aspects of immunotherapy, emerging immunotherapies (both prophylactic and preventive) and different vaccination approaches. The novel, and, at the same time, established character of computation in immunology greatly improves and speeds-up the development of novel vaccination strategies, both therapeutic and preventive, against cancer. We welcome original research, methodology, software, and database article submissions.

The deadline for submission of manuscripts is 30thNovember2017. For more information, visit the BMC Immunology website.

References

View the latest posts on the BMC Series blog homepage

By commenting, youre agreeing to follow our community guidelines.

Go here to see the original:
New Thematic Series for BMC Immunology: Cancer Immunotherapy ... - BMC Blogs Network (blog)

We Should Still Humans And Why It’s Critical in the Digital Age – HuffPost

Last week, I met famed futurist Ray Kurzweil who told me that it is virtually certain that I will be a cyborg in about 15 years. Sweet cant wait for that.

I was at Singularity Universitys Exponential Manufacturing conference, where the program inspired roughly equal amounts of excitement and sheer terror in me and my fellow attendees. The impact of exponentials is clearly going to change the world that we live in and who we are and perhaps nowhere more noticeably than in the manufacturing world. Robots will take over some production lines. Additive processes and advances in material science will fundamentally change what we can make. Sensors and advanced analytics will create an ability essentially to erase machine downtime.

As we prepare to compete in such a world, its easy to focus all our attention on the technologies that are arriving on the scene every day. Startups and big incumbents alike (think GE) are delivering enablers of digital transformation faster than ever before. It feels urgent that we keep up and not get left behind. Many say that if you are not in-the-know on technological trends, youre already dead you just dont know it yet.

Dont worry about it. In fact, I recommend we stop trying to keep track of it all.

Start with Human Beings. It used to be that a perfectly reasonable approach to creating advantage from technology was to follow a straightforward and linear approach: Start with a technology in mind and imagine the potential applications within your operations. From there, layer on top an approach to either access or use data to optimize the application. Prototype the solution and go try it out in a pilot plant and see what happens. If it has a positive ROI, scale it; if not, shut it down.

Thats no longer possible in most cases. The reality is that it has already become virtually impossible to keep track of all the technologies available, never mind the almost infinite possible applications and business models. So I recommend flipping the approach around: Start with humans, not technology, and you are bound to be far more successful.

The Power of Behavior. Human behavior is still and for the foreseeable future the most basic building block of economic value for any organization. Whether you are targeting growth or efficiency, you are not going to achieve your goal unless someone, somewhere changes a behavior. So the job that any good manager has is to identify the right behavior to impact and then to discover ways to drive it in as efficiently as possible from an economic perspective.

If we can start with human behavior, then we can reverse the process described above and turn it into three sequential strategic choices:

Instead of spending evermore time trying to stay abreast of new technological developments, we should instead just search selectively for the ones which will drive the most value from digital innovation.

Three Behavioral Domains. As you search for the right possible behavior to target, you should consider three environments for behavioral change: outcomes in your own operations, outcomes for downstream customers, and outcomes in markets. Those focused on your own operations are usually aimed at driving efficiency and reducing costs. Those focused on customers or end-markets are usually targeting topline growth.

At the Exponential Manufacturing conference, I gave a talk which laid out this logic and brought to life examples of each of these with three companys stories:

In these ways, human beings and not technology alone can be at the heart of digital transformation.

Terminator. Of course, none of this changes the fact that Ray Kurzweil is almost certainly right about me and you being a cyborg some time in the 2030s. After all, this is the guy who is famous for getting his far-fetched predictions right. As he relayed to us, he made about 150 predictions back in 1999 for what was going to change in the ensuing decade. He got 86% of them right. But when asked which ones he didnt get right, he explained that they were the ones where human behavior (e.g. adoption, regulation) threw a wrench in the works by being far less predictable than technological advances.

Its nice to know that we still matter. For now.

Start your workday the right way with the news that matters most.

Go here to read the rest:
We Should Still Humans And Why It's Critical in the Digital Age - HuffPost

Understanding anthropogenic effects on space weather – MIT News

Effects of human behavior are not limited to Earth's climate or atmosphere; they are also seen in the natural space weather surrounding our planet. "Space weather" in this context includes conditions in the space surrounding Earth, including the magnetosphere, ionosphere, and thermosphere.

A recent survey by a team of scientists including Phil Erickson, assistant director of MIT Haystack Observatory, has resulted in an article in the journal Space Science Reviews. The study provides a comprehensive review of anthropogenic, or human-caused, space weather impacts, including some recent findings using NASA's Van Allen Probes twin spacecraft.

As space scientist James Van Allen discovered in the 1950s and 1960s, two radiation belts surround Earth with a slotbetween them. The inner edge of the outer Van Allen radiation belt is particularly interesting, as it is composed of high-energy "killer" electrons that have the potential to permanently damage spacecraft. Tracking the inner edge of the radiation belt is important for GPS navigation, communication, and other satellite-based systems to help protect them from this naturally occurring radiation.

Until recently, it was thought that the inner edge of the outer belt was under nearly all conditions located at the plasmapause, the outer boundary of cold, dense plasma surrounding Earth that is produced daily by the sun's extreme ultraviolet rays. During geomagnetic storms, extra energy from solar flares and coronal mass ejections interact with and compress the plasmasphere. Scientists originally thought that under these conditions, the inner edge of the outer Van Allen belt would contract with the compression of the plasmasphere and move closer to Earth.

Research using the Van Allen Probes has discovered instead that during particularly intense geomagnetic storms, the inner edge of the outer belt does not follow suit but instead keeps its distance from the Earth, holding off the inner extent of "killer electrons" possessing damage potential. This inner limit to high-energy electrons occurs at the edge of strong human-origin radio transmissions created for a very different purpose.

Space weather which can include changes in Earth's magnetic environment is usually triggered by the sun's activity, but recently declassified data on high-altitude nuclear explosion tests have provided a new look at the mechanisms that set off perturbations in that magnetic system. Such information can help support NASA's efforts to protect satellites and astronauts from the natural radiation inherent in space.

Video: Genna Duberstein/NASA Goddard Space Flight Center

Strong very low frequency (VLF) radio waves have been used for nearly a century to communicate with submarines, as they penetrate seawater well. But in addition to traveling through the ocean, the VLF waves also propagate upward along magnetic field lines and form a "bubble" of VLF transmissions, reaching to about the same spot that the ultra-relativistic electrons seem to stop during superstorms. The communications signals can interact with and remove some of these high-energy particles through loss to our atmosphere. This new understanding implies that human-origin systems can have an unexpected effect on high-energy space weather around our planet during these unusual, intense storms in space.

The Space Science Reviews survey also explores a more direct effect caused by humans on the near-Earth space environment. High-altitude nuclear detonation tests during the Cold War also affected the near-Earth environment by creating long-lasting artificial radiation belts that disrupted power grids and satellite transmissions. Such tests are now banned: In particular, the 1963 Partial Test Ban Treaty signed by all nuclear powers at the time specifically prohibits nuclear weapons testing in the atmosphere. However, a large body of information on the effects of these atmospheric tests exists, and the article examines these historical nuclear explosions to further study of anthropogenic effects on space weather.

Understanding human-origin space weather under these extreme conditions allows us to greatly enhance our knowledge of natural effects and allows essential engineering and scientific work aimed at protecting the planet's ground-based and satellite technology. Nuclear atmospheric tests were a human-generated and extreme example of some of the space weather effects frequently caused by the sun, says Erickson. If we understand what happened in the somewhat controlled and definitely extreme conditions caused by one of these man-made events, and combine it with studies into longer term effects such as the VLF communications 'bubble,' we can more readily advance our knowledge and prediction of natural variations in the near-space environment.

The work highlights the importance of continuing research into space weather both naturally occurring effects and those influenced by human behavior as an essential part of society's advance toward a more complex, spacefaring society.

Here is the original post:
Understanding anthropogenic effects on space weather - MIT News

Coyote bites 5-year-old girl in Scottsdale park – AZCentral.com

Kelsey Mo, The Republic | azcentral.com Published 12:29 p.m. MT May 31, 2017 | Updated 10 hours ago

A coyote was caught on Robbie Hackett's dash camera as it ran across the street in Gilbert. azcentral.com

1 of 3

Marilyn McLauchlan talks about recent coyote encounters and her efforts to keep them away Wednesday, March 16, 2016 in Sun City Grand, Ariz.

2 of 3

Scottsdale police help rescue a coyote that got stuck in a resident's fireplace.

3 of 3

Coyote caught on car dash camera

How to keep coyotes away from family and pets

Scottsdale police free coyote from fireplace

This coyote, wandering through a parking area at Mesa Community College, may be late for class, but is probably hunting for food.(Photo: Michael Chow/The Republic)

A young girl was treated and released from a hospitalafter being bitten by a coyote at a Scottsdale park, according to the Arizona Game and Fish Department.

The 5-year-old girl was bitten in the thigh whileplaying Tuesday night at Thompson Peak Park with her mother and two younger siblings.

She had been sitting at the edge of a slide with a granola bar in her hand, unaware that a coyote was resting in the shade underneath, officials said.

"There's no way for us to speculate on whether that (the granola bar)had anything to do with the bite, but it's definitely something for people to be aware of," saidAmy Burnett, a Game and Fish spokeswoman.

The girl did not need stitches and was released from the hospital after undergoing precautionary treatment for rabies, Burnett said.

MORE: Have you seen a coyote in your neighborhood lately? Heres why

Game and Fish employees killeda coyotethey found in the park near Loop 101 and Hayden Road on Tuesday night, and Burnett said that she received word from a contractor with Game and Fish that a second coyote had been removed from thearea Wednesday morning.

"Witnesses said they've seen up to three coyotes ... inthe vicinity of the park," Burnett said.

Given the unusual behavior of the coyote approaching humans, Burnett said, there is a high chance that it was being fed in the neighborhood.

"Fed coyotes become accustomed to people," she said. "They come around a little too close, they become bold, and it can sometimes lead to a situation where animals and humans interact negatively, and it's a good reminder for everyone not to feed wildlife."

Though it is not uncommon for coyotes to be inthe areabecause of its close proximity to open space, human behavior could keep them coming around more often, Burnett said.

Several factors in the urban area, including the water,grass and access to food in the park area invite coyotes to approach humans and creates this cycle where coyotes view humans as a good thing.

"The best thing to do is to leave them wild," Burnett said. "When you feed them, you're changing their behavior, and they're no longer the animals you want to see in our desert roaming free. It never works out well for the people or for the animals."

READ MORE:

A look back at 20 great albums released in 1967

Collision between bicycle, commercial truck turns deadly in Gilbert

New-home sales in Phoenix area up 22 percent; rising prices are not far behind

Read or Share this story: http://azc.cc/2rFzuT0

Original post:
Coyote bites 5-year-old girl in Scottsdale park - AZCentral.com

Hillsboro Native Earns Honors At Vanderbilt – thejournal-news.net

Hillsboro native Dr. Nancy J. Cox was honored this spring as the first recipient of the Richard M. Caprioli Research Award. Dr. Cox is currently the director of the Vanderbilt Genetics Institute in Nashville, TN.

The daughter of the late Gene and Helen Cox, she is a 1974 graduate of Hillsboro High School and was selected as the second Hillsboro Education Foundation Distinguished Alumni Award recipient in 2002.

Dr. Cox earned her bachelor of science degree in biology from the University of Notre Dame in 1978 and her doctorate in human genetics from Yale University in 1982.

She completed a postdoctoral fellowship in genetic epidemiology at Washington University and was a research associate in human genetics at the University of Pennsylvania.

In 1987, she was hired at the University of Chicago. She was appointed full professor in the departments of medicine and human genetics in 2004 and chief of the section of genetic medicine the following year.

In 2012, she was named a University of Chicago Pritzker Scholar. In 2015, Dr. Cox was hired at Vanderbilt University School of Medicine as the Mary Phillips Edmonds Gray Professor of Genetics, founding director of the Vanderbilt Genetics Institute and director of the Division of Genetic Medicine in the Department of Medicine. She is a fellow of the American Association for the Advancement of Science

Throughout her career as a quantitative geneticist, Dr. Cox has sought to identify and characterize the genetic component to common human diseases and clinical phenotypes like pharmacogenomics traits (how genes affect drug response).

Her work has advanced methods for analyzing genetic and genomic data from a wide range of complex traits and diseases, including breast cancer, diabetes, autism, schizophrenia, bipolar disorder, Tourette syndrome, obsessive-compulsive disorder, stuttering and speech and language impairment.

Through the national Genotype Tissue Expression (GTEx) project, Dr. Cox also contributed to the development of genome predictors of the expression of genes, and she also has investigated the genetics of cardiometabolic phenotypes such as lipids, diabetes and cardiovascular disease.

With colleagues at the University of Michigan, Dr. Cox is generating content for the Accelerating Medicine Partnership between the National Institutes of Health (NIH), U.S. Food and Drug Administration, biopharmaceutical companies and non-profit organizations. The goal of the partnership is to identify and validate promising biological targets, increase the number of new diagnostics and therapies for patients, and reduce the cost and time it takes to develop them.

Dr. Cox is co-principal investigator of an analytic center within the Centers for Common Disease Genomics, another NIH initiative that is using genome sequencing to explore the genomic contributions to common diseases such as heart disease, diabetes, stroke and autism. A major resource for the Cox lab is Vanderbilts massive biobank, BioVU, which contains DNA samples from more than 230,000 individuals that are linked to de-identified electronic health records.

Dr. Cox is the author or co-author of more than 300 peer-reviewed scientific articles. She is former editor-in-chief of the journal Genetic Epidemiology, and is the current president of the American Society of Human Genetics.

For developing new methods that have aided researchers worldwide in identifying and characterizing of the genetic and genomic underpinnings of diseases and complex traits, Dr. Cox is the first recipient of the inaugural Richard M. Caprioli Research Award.

Dr. Cox and her husband, Dr. Paul Epstein live in Nashville, TN, and have two grown daughters, Bonnie Epstein and Carrie Epstein.

Read more:
Hillsboro Native Earns Honors At Vanderbilt - thejournal-news.net

Myriad Genetics to Present at the 2017 William Blair Growth Stock Conference – GlobeNewswire (press release)

May 31, 2017 16:05 ET | Source: Myriad Genetics, Inc.

SALT LAKE CITY, May 31, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the William Blair Growth Stock Conference at 12:40 p.m. CDT on June 14, 2017, at the Four Seasons Hotel in Chicago, Illinois.

The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriads website at http://www.myriad.com.

About Myriad Genetics Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Related Articles

Salt Lake City, Utah, UNITED STATES

Myriad Genetics, Inc. Logo

LOGO URL | Copy the link below

Formats available:

Read the original post:
Myriad Genetics to Present at the 2017 William Blair Growth Stock Conference - GlobeNewswire (press release)

Italian Journal of Anatomy and Embryology

The Italian Journal of Anatomy and Embryology was founded in 1901 by Giulio Chiarugi, Anatomist at Florence University, and hence ever devoted to the progress and diffusion of science in the fields of Anatomy, Histology and Embryology. The Journal will continue to be devoted to publish original, research or review papers dealing with the entire field of anatomy and embryology of vertebrates, from clinical anatomy to cell and developmental biology, with special regard to human and veterinary medicine and including medical education in those fields.

Assistant Editors Maria Simonetta Pellegrini Faussone Gabriella B. Vannelli

Past-Editors I. Fazzari E. Allara G.C. Balboni E. Brizzi G. Gheri

Editorial Board

Giuseppe Anastasi (Professor of Anatomy, University of Messina, Italy) Pepa Atanassova (Professor of Histology, Plovdiv, Bulgaria) Daniele Bani (Professor of Histology, University of Florence, Italy) Raffaele De Caro (Professor of Anatomy, University of Padua, Italy) Mirella Falconi Mazzotti (Professor of Anatomy, University of Bologna, Italy) Antonio Filippini (Professor of Histology, University of Rome "La Sapienza", Italy) Eugenio Gaudio (Professor of Anatomy, University of Rome "La Sapienza", Italy) Krzysztof Gil (Associate Professor of Pathophysiology, Jagiellonian University of Krakow, Poland) Menachem Hanani (Emeritus of Physiology, Hebrew University of Jerusalem) Nadir M. Maraldi (Emeritus of Histology, University of Bologna, Italy) Hanne B. Mikkelsen (Professor of Anatomy and Cell Biology, University of Copenhagen) Giovanni Orlandini (Emeritus of Anatomy, University of Florence, Italy) Maria Simonetta Pellegrini Faussone (Emeritus of Histology, University of Florence, Italy) Laurentiu M. Popescu (Bucharest, Romania) Alessandro Riva (Emeritus of Anatomy, University of Cagliari, Italy) Ajai K. Srivastav (Professor of Zoology, Gorakhpur, India) Gabriella B. Vannelli (Professor of Anatomy, University of Florence, Italy)

Italian Journal of Anatomy and Embryology is indexed in:

See the original post here:
Italian Journal of Anatomy and Embryology

Venous embryology: the key to understanding anomalous …

Download this issue Back to summary

Byung-Boong LEE

Professor of Surgery and Director, Center for Lymphedema and Vascular Malformations, George Washington University School of Medicine, Washington DC, USA

Venous embryology can explain many of the defects resulting in venous anomalies in later life, yet is often overlooked. Venous malformations are vascular malformations that only affect the venous system. They are classified into two different types depending on the embryological stage when the defective development occurs. Venous malformations originating during the early stage of embryogenesis are termed extratruncular, while those originating during the late stage of embryogenesis are classified as truncular. A defect at any point in the complex development stages of the evolution and involution of multiple paired embryonic veins can result in various conditions of defective venous trunkTherefore, truncular lesions in general are associated with more serious hemodynamic consequences than extratruncular lesions due to their direct involvement with the truncal venous system.

This review provides a detailed overview of venous embryology and a number of truncular venous malformations to illustrate how a thorough knowledge of this subject can aid in their diagnosis and treatment.

A thorough understanding of vascular system anatomy is a prerequisite for all vascular specialists. However, a knowledge of venous embryology is seldom acquired even though all mature and named vessels originate from their precursor, embryonic vessels, and vascular anomalies are closely linked to them.

Vascular anomalies are relatively rare and difficult to understand and interpret. Yet, venous embryology is one of the most neglected areas of basic science in medicine despite its critical ability to explain the many obscure conditions related to anomalous anatomy (eg, membranous occlusion of suprahepatic inferior vena cava as a cause of primary Budd-Chiari Syndrome).1,2

Such venous anomalies are a result of the defective development of embryonic veins during the vascular trunk formation period in the later stage of embryonic development.3,4 A benign narrowing (stenosis) of the jugular-azygos vein system is a good example of how defective development can cause a unique condition, in this case chronic cerebrospinal venous insufficiency (CCSVI).5,6

A basic knowledge of vascular embryology and in particular, the evolutional and involutional development of the venous system involved in the maturation of the truncal vein, is essential for the recognition and interpretation of a number of venous anomalies.7,8

When the embryo starts to grow at an exponential rate in the early stage of embryogenesis, rapid growth and expansion of the embryonic vessels must follow suit to fulfill their critical role as the channels to supply essential nutrient requirements. A defect at any point in the complex development stages of evolution and involution of multiple paired embryonic veins can result in congenital vascular malformations (CVM).9,10 The prevalence of defective development in the vascular structure of the newborn is in the range of 1% to 3%.

As CVMs are birth defects that arise during the various stages of development of the vascular system,11,12 they can involve one or more components: artery, vein, lymphatics, and/or capillary vessels. Venous malformations are vascular malformations that only affect the venous system.13,14 They may exist alone as an independent lesion or combined with other CVMs as lymphatic malformations,15,16 arteriovenous malformations,17,18 and/or capillary malformations.19,20 The clinical behavior of the malformation is solely dependent on the embryonic stage at which the developmental arrest/defect occurs.

When defective development occurs in the early stage of embryogenesis, the embryonic vessels remain in the form of reticular networks and do not evolve into the vascular trunk formation. After birth these networks can remain as independent clusters of primitive venous tissue without direct involvement of the main venous trunk itself (eg, extratruncular venous malformation) (Figure 1). These primitive vascular structures maintain the mesenchymal cell properties and its evolutional ability to proliferate when stimulated by exogenous (eg, surgery, trauma) or endogenous factors (menarche, pregnancy, female hormones).7,8,10,21,22

When defective development occurs in the vascular trunk formation period in the later stage of embryonic development, the defects involve named vessels (eg, iliac, femoral, and popliteal vessels) and are limited to the vessel trunk itself. Examples of such truncular venous malformations include popliteal vein aneurysm, absence/aplasia of the femoral vein, jugular vein stenosis/webs, and hypoplastic iliac vein (Figure 2). These are embryologically mature lesions, which no longer possess the evolutionary capacity to proliferate. However, truncular lesions present with more serious hemodynamic consequences in general compared with extratruncular lesions due to their direct involvement with the truncal venous system (eg, avalvulosis, marginal veins, popliteal vein aneurysm, inferior vena cava stenosis/occlusion).23,24

Figure 1 (A D). Extratruncular venous malformation (VM) 1A depicts a clinical condition of extratruncular venous malformation (VM) lesions affecting the entire left lower leg, but mostly limited superficially to the soft tissue level. 1B (whole body blood pool scintigraphy) displays compatible findings to show the extent of the lesion on the same extremity. On the contrary, 1C shows a benign looking VM lesion in the right lateral upper thigh mimicking varicose veins. However, it is the tip of the iceberg of extensive lesions infiltrating into the surrounding soft tissue as well as the muscles, shown in MRI (1D).

Figure 2 (A and B). Truncular venous malformation (VM) 2A demonstrates angiographic findings of a truncular VM lesion consisting of an aneurysmal dilatation of the right popliteal vein; this truncular lesion is the outcome of developmental arrest during the vascular trunk formation period in the later stage of embryonic development. 2B also presents angiographic findings of another type of truncular VM lesion this time a stenotic condition involving the right internal jugular vein trunk along its junction with the superior vena cava (Courtesy of Professors P Zamboni and R.Galeotti for 2B).

Based on the above definitions, the modified Hamburg Classification separates venous malformations into two different types: extratruncular and truncular, depending on the embryological stage when the defective development occurred (Table I).25,26 Venous malformations originating from the early stage of embryogenesis are classified as extratruncular together with all other types of vascular malformation from the same early stage (eg, lymphangioma). Venous malformations originating from the late stage of embryogenesis are classified as truncular.

As all truncular lesions involve the already formed, established venous trunk to varying degrees, they present as either hypoplastic or hyperplastic vessels/lesions causing obstruction or dilatation (eg, internal jugular vein aneurysm, iliac vein stenosis), depending on the defect.27,28 It should be noted that intraluminal defects within the vein (eg, vein webs or membrane) can result in similar conditions of stenosis or obstruction (Figure 3).29,30

Table I. The modified Hamburg classification of congenital vascular malformations. * Based on the predominant vascular structure in the malformation. ** Based on anatomy and developmental arrest at the different stages of embryonic life: extratruncular form from earlier stages; truncular form from late stages.

Figure 3 (A and B). Truncular venous malformation (VM) 3A shows angiographic findings for a truncular VM lesion involving a segmental stenosis of the left iliac vein. This benign looking condition precipitated a severe chronic venous insufficiency to the affected lower extremity. 3B shows another form of truncular VM involving an aneurysmal dilatation of the right internal jugular vein (Courtesy of Professors P. Zamboni and R. Galeotti for 3B).

Less frequently, truncular venous malformations may present as a persistent fetal remnant vein that has failed to involute or regress normally. This unique condition, which involves the lower extremity venous system, is known as marginal/sciatic/lateral embryonic veins31,32 and represents the venous malformation component of Klippel-Trenaunay Syndrome (Figure 4).3,4,21,22

As a consequence of their direct involvement with the venous system, the chronic venous congestion and hypertension due to venous reflux or occlusion caused by truncular venous malformations result in more tissue and organ damage than extratruncal lesions. Membranous, focal, or segmental lesions can cause suprahepatic stenosis of the inferior vena cava along the proximal terminal segment, a condition known as primary Budd-Chiari syndrome. This has a profound hemodynamic impact, not only on the lower extremities where it causes chronic venous hypertension, but also on the liver where it results in severe portal hypertension due to hepatic venous outlet obstruction. This congenital/developmental anomaly most frequently involves Asian and African races (Figure 5).33,34

The cerebrospinal venous circulation is not exempt from truncular venous malformations. Cerebrospinal venous malformations carry the potential risk of long-term chronic venous hypertension to the brain resulting in various clinical conditions/illnesses such as CCSVI.35,36

An example of CCSVI, internal jugular vein valve incompetence (IJVVI), has been postulated to be the cause of transient global amnesia.37,38 IJVVI is diagnosed when retrograde jugular vein flow is detected by extracranial duplex ultrasound during Valsalva maneuver. It is believed that IJVVI may produce transient mesiotemporal ischemia by venous congestion. This mechanism requires a patent venous pathway from the affected internal jugular vein through the transverse sinus, confluence, straight sinus, and vein of Galen into the basal vein of Rosenthal and into the internal cerebral veins.

Figure 4 (A and B). Truncular venous malformation: marginal/lateral embryonic vein 4A depicts a clinical condition of the marginal/lateral embryonic vein along the lateral aspect of the left lower extremity. This unique vein structure is a persistent fetal remnant vessel following the failure of normal involution/regression and its avalvulosis causes severe venous reflux. Marginal vein remains are a hallmark of Klippel-Trenaunay syndrome, representing its venous malformation component. 4B presents angiographic findings of this marginal vein, which is the only remaining major venous drainage route with a lack of normal development of the deep venous system. Surgical excision to control venous hypertension is therefore contraindicated.

Figure 5 (A D). Suprahepatic inferior vena cava (IVC) occlusive lesion: primary Budd-Chiari syndrome A common cause of suprahepatic IVC occlusion is focal stenosis (shown in 5A and 5B) and segmental stenosis (5C), although membranous bstruction by the web is the most common cause among Asians (5D). These are relatively simple congenital VM, which develop during the late vessel trunk formation stage. However, they have a profound hemodynamic impact on the liver with portal hypertension due to hepatic venous outlet obstruction in addition to chronic venous insufficiency affecting the lower extremities.

There are now also data supporting a role for CCVI in the development of multiple sclerosis as reported in the International Union of Phlebology Consensus on Venous Malformations 2009.39 It is hypothesized that truncular venous malformations causing stenosis along the internal jugular, innominate, superior vena cava, and azygos vein system, may contribute to the development or exacerbation of multiple sclerosis.40,41

The heart and blood vessels develop from the mesoderm as isolated masses and cords of mesenchymal cells as early as 15 to 16 days in order to rapidly deliver sufficient nutrients to the exponentially proliferating cells and dispose of waste products via connection with maternal blood vessels in the placenta.42-44 By the beginning of the fourth week of gestation, an extensive network of blood vessels has formed from the mesenchyme as clusters of angiogenetic cells throughout the embryonic body to establish a communication with extra-embryonic vessels and to create a primitive vascular system: the Vitelline- Umbilical-Cardinal Vein System (Figures 6 and 7).42-44

The primitive vascular structure in complex capillary and reticular plexuses in the early embryonic stage is soon replaced by the newly developed paired cardinal veins as an axial, truncal venous system. In addition, the paired vitelline vessels from the yolk sac develop into the hepatic portal system, while the paired umbilical vessels from the chorion and body stalk form the ductus venosus. The anterior and posterior cardinal veins merge to become the common cardinal veins, draining centrally into the sinus venosus (sinus horns) and also receiving the vitelline and umbilical veins (Figure 6). At 4 weeks, the paired umbilical veins return blood from the placenta to capillary networks in the liver. During the fifth week of development, the right umbilical vein degenerates, involutes together with the proximal portion of the left umbilical veins, leaving only the distal part of the left umbilical vein as a single vein to return blood from the placenta to the embryo.

Figure 6. Embryonic veins at the fifth week of gestation: anterior/posterior/common cardinal vein and vitelline/umbilical vein developmental process The embryo demonstrates the development of paired sets of vitelline and umbilical veins in its fifth week, which initially drain the yolk sac and allantois, but later drain the intestines and the placenta, respectively. Paired sets of anterior and posterior cardinal veins join to form the common cardinal veins, draining centrally into the sinus venosus. The common cardinal veins also receive vitelline and umbilical veins, as depicted.

Figure 7. Embryonic veins at the seventh week of gestation: vitelline/umbilical vein developmental process At the seventh week of embryonic development, the entire right umbilical vein and proximal left umbilical vein regress. The distal left umbilical vein subsequently anastomoses with the hepatic sinuses to form the ductus venosus. The ductus venosus allows venous blood from the umbilical vein and the portal vein direct access to the inferior vena cava (IVC). The distal/upper-most segment of the right vitelline vein remains as the most proximal segment of the IVC reaching the heart via paired sinus venosus, while all other parts of the vitelline veins regress/involute completely.

At 8 weeks, the distal left umbilical vein anastomoses with the hepatic sinuses to form the ductus venosus. This newly formed structure allows venous blood from the umbilical vein and portal vein to bypass the liver and flow into the inferior vena cava and finally to reach the heart via the paired sinus venosus (Figure 7).

The part of the body distal to the developing heart (head, neck, upper torso, and upper limbs) drains through the bilateral anterior cardinal veins also known as the precardinal veins, whereas, the caudal portion of the body (body and lower limbs) drains through the bilateral posterior cardinal veins also known as the postcardinal veins.45,46

Numerous large tributary vessels develop from the anterior cardinal veins and converge as cerebral plexuses. Blood passes from the plexuses to the heart through the anterior cardinal and common cardinal veins. The anterior cardinal (precardinal) veins, common cardinal, and terminal/proximal posterior cardinal (postcardinal) veins go through a major evolutionary process to become the veins of the heart, the superior vena cava (SVC), and its tributaries.

Paired anterior cardinal veins anastomose to allow blood to drain from the left anterior cardinal vein into the right anterior cardinal vein. This anastomosis grows from the left anterior cardinal vein to the right anterior cardinal vein to form the left brachiocephalic (innominate) vein.

The portion of the left anterior cardinal vein distal to the anastomosis, becomes the left internal jugular vein and joins the left subclavian vein from the developing upper limb. The left anterior cardinal vein proximal to the brachiocephalic anastomosis regresses/atrophies with the terminal segment of the left posterior cardinal vein, ultimately becoming the Great Cardiac Vein. The oblique vein of the left atrium (Vein of Marshall) at the back of the left atrium and the coronary sinus of the heart comprise the Great Cardiac Vein. The distal portions of the bilateral anterior cardinal veins therefore become the bilateral internal jugular veins and the blood from the left internal jugular vein passes through the left brachiocephalic vein, draining directly into the SVC (Figure 8).47,48

On the right-hand side, the proximal part of the right anterior cardinal vein forms the SVC with the right common cardinal vein in conjunction with the right horn of the sinus venosus (Figure 8). The SVC therefore consists of three different segments: 1. Right anterior cardinal vein proximal to the brachiocephalic anastomosis 2. Right common cardinal vein 3. Right horn of the sinus venosus

These veins are further involved in the formation of the arch of azygos vein together with the proximal segment of the right posterior cardinal vein. The termination of the left posterior cardinal vein transforms into the Great Cardiac Vein, which drains into the left atrium. The azygos venous system is initially derived from the paired supracardinal venous systems, one of three cardinal veins that drain the caudal portion of the body together with the postcardinal (posterior cardinal) veins.49,50

Figures 8 (top) and 9 (bottom). Precardinal/anterior cardinal vein developmental process Paired anterior cardinal veins form common cardinal veins with paired posterior cardinal veins, draining centrally into the sinus venosus (sinus horns) as depicted. Paired anterior cardinals soon form an anastomosis between them; the connection grows from the left to the right anterior cardinal vein to form the left brachiocephalic (innominate) vein. The left anterior cardinal vein distal (cranial) to the anastomosis becomes the left internal jugular vein, while the left anterior cardinal vein proximal to the brachiocephalic anastomosis regresses/atrophies to become the base of the coronary sinus of the heart as displayed. The right anterior cardinal (precardinal) vein proximal to the right brachiocephalic vein forms the superior vena cava (SVC) with the common cardinal, and terminal/proximal segment of the posterior cardinal (postcardinal) vein.

Three sets/pairs of cardinal veins: precardinal, postcardinal, and supracardinal, evolve to form the azygos venous system. The azygos venous system is initially derived from the paired supracardinal vein. The proximal segment of the right supracardinal vein forms the arch of azygos vein together with the cranial part of the right posterior cardinal vein, while the cranial part of the left supracardinal vein becomes the hemiazygos and also accessory azygos veins as displayed in 9. The hemiazygos vein on the left side drains into the azygos vein located in the right side before draining into the SVC. The accessory hemiazygos vein runs along the course of the involuted left common cardinal vein and drains into the hemiazygos vein before it crosses over the midline to the azygos vein.

The right supracardinal vein remains as the azygos vein together with the distal portion of the right posterior cardinal vein to form the arch of azygos vein. The left supracardinal vein becomes the hemiazygos vein and accessory azygos vein. The hemiazygos vein on the left drains into the azygos vein located on the right side and subsequently into the SVC. The accessory hemiazygos vein, which runs along the course of the involuted left common cardinal vein, drains into the hemiazygos vein before it crosses the midline to flow into the azygos vein (Figure 9).

Due to the complex nature of the various stages of evolution and involution of multiple paired embryonic veins, several anomalous conditions associated with the SVC can develop. These may affect the common cardinals, anterior and posterior cardinals, and primitive jugular veins. The likelihood of development anomalies associated with the SVC is relatively high due to the involvement of three different embryonic vein segments.

For example, a left-sided SVC may develop from persistent left anterior and left common cardinal veins,51,52 and is often associated with the absence of the right SVC.53,54 In this condition, the right brachiocephalic vein crosses the midline to join a vertical left brachiocephalic vein, thus forming a left SVC. As a consequence of this developmental defect of the common cardinal vein, the persistent left SVC can be associated with the presence of two azygos veins. When a left SVC is present, the anatomy of the azygos veins may be reversed; the hemiazygos vein (the remnant of the proximal part of the left posterior cardinal vein) located on the left, will drain directly into the left-sided SVC, in the way that a normal azygos vein (the remnant of the proximal part of the right posterior cardinal vein) would drain into the SVC on the right side. This anomalous condition is the result of a developmental arrest/defect during the late stage of embryogenesis. The left SVC is grouped with other similar truncular venous malformations (eg, double SVC, internal jugular vein stenosis/aneurysm).

A double SVC is another well-known vein anomaly that occurs as a result of failure of degeneration/involution of the left anterior cardinal vein proximal to the brachiocephalic anastomosis.55,56 The double SVC is further subgrouped based on combined anomalous veins.

The posterior cardinal (postcardinal) veins are the first pair of embryonic veins to arise that drain the caudal body. They soon become integrated and taken over by the newly developing subcardinal and supracardinal veins.57-59 The shift of the systemic venous return to the right atrium in early embryonic life initiates the radical remodeling of these cardinal (embryonic) venous systems. The postcardinal, subcardinal, and supracardinal veins go through extensive evolution as well as involution for complex remodeling to form the inferior vena cava (IVC), which drains the trunk and lower extremities (Figure 10).60,61

Figure 10 (A-C). Developmental process for the inferior vena cava involving postcardinal, supracardinal, and subcardinal veins Three pairs of the post-/sub-/supracardinal veins go through extensive evolution and involution to form the inferior vena cava (IVC) as well as hepatic veins, together with the bilateral vitelline and umbilical veins. The role of postcardinal (posterior cardinal) veins, the first pair of embryological veins for venous drainage of the caudal body, is soon taken over by developing pairs of subcardinal and supracardinal veins, to form the IVC as shown.

The IVC is formed in a complicated series of developmental stages from the following embryonic structures (Figure 11): 1. Suprahepatic the most proximal segment of the IVC develops from the persistent proximal portion of the right vitelline vein, which is the precursor of the common hepatic vein. 2. A new hepatic segment develops from an anastomosis between the right vitelline vein and the right subcardinal vein distal/dorsal to the developing liver to connect this proximal-most (suprahepatic) segment to the distally located right subcardinal vein, while allowing drainage of the hepatic veins/liver. 3. The renal/mesenteric segment of the IVC is represented by a preserved segment of the right subcardinal vein. 4. The new junctional segment of the IVC is formed through an anastomosis between the right subcardinal vein and the more distally located right supracardinal vein. 5. The infrarenal segment is represented by the preserved segment of the right supracardinal vein. 6. The last segment of the IVC is formed as a new segment to connect the right supracardinal and most distal part of the bilateral posterior cardinal veins.

The IVC therefore undergoes a complicated fusion of multiple segments of different embryonic veins: vitelline, supracardinal, subcardinal, and posterior cardinal, anastomoses between these veins, as well as between sub- and supracardinal veins. As a result there is a high likelihood of developmental anomalies occurring during this complicated embryogenic process.

The complex embryological development is such that variations and anomalies are common where embryological connections persist, either alone or in conjunction with aplasia or hypoplasia of normally developing channels.62,63 There are therefore many different congenital anomalies of the IVC involving its length, location, duplication, abnormal connection and draining, and residual remnants of the embryonic tissue such as webs, membranes, etc.

Double/duplicated IVC occurs as a result of the bilateral persistence of the supracardinal veins,64,65 while a leftsided IVC is the result of caudal regression of the right supracardinal vein instead of the left supracardinal vein, which fails to involute/regress and persists (Figure 11).66,67

The absence of the suprarenal IVC arises from cava/iliac vein agenesis.68,69 When the right subcardinal vein fails to anastomose with the liver, the IVC drains into the arch of the azygos vein and the hepatic veins drain independently through the diaphragm into the right atrium (Figure 12). A posterior/retroaortic left renal vein is another example of defective regression of the anterior portion of the renal ring (1%-2%).70,71

Figure 11 (A-C). Left-sided IVC (11A) is one of the IVC anomalies that occurs as a result of failure of normal evolution and involution of the three pairs of cardinal veins. Other related anomalies are Double/ duplicated IVC (11B) and absence of IVC development (11C).

Figure 12. Failure of subcardinal vein to anastomose with the liver When normal anastomosis of the right subcardinal vein with the liver fails due to abnormal development of the hepatic segment of the IVS, the distal part of the IVC drains directly into the arch of the azygos vein and the hepatic veins drain independently through the diaphragm into the right atrium.

Membranous, focal, segmental, and obstructive lesions in the suprahepatic IVC belong to a group of intraluminal defects of the vein wall that cause varying degrees of stenosis and obstruction, and together with venectasia and aneurysm cause venous dilatation.72,73

Truncal venous development of the lower extremities occurs in three phases to form matured veins in the later stage of embryogenesis (Figure 13).74,75

First phase: primitive fibular (peroneal) vein Early venous outflow from the primitive lower limb occurs through a lateral/posterior fibular (peroneal) vein into the posterior cardinal vein; this is the first embryonic vein of the limb.

Figure 13 (A and B). Truncal venous development of the lower extremities occurs in three phases. 13A (left) depicts the first phase of truncal vein development involving evolution of the primitive fibular (peroneal) vein, which becomes the first embryonic vein of the lower limb. In the second phase (right), the primitive fibular vein develops two branches: the anterior tibial vein and connecting branch. The anterior tibial vein and primitive fibular veins together now constitute the sciatic vein, which is the second embryonic vein. 13B (left) illustrates the third phase in which the femoral vein is formed by a connecting branch from the middle of the sciatic vein, to establish a new definitive deep venous system. The sciatic vein (right) regresses and the femoral vein is further evoluted, following anastomoses with sciatic veins, and passes down the leg as the posterior tibial vein to complete the evolution of the veins along the lower limb.

Second phase: sciatic vein The primitive fibular vein develops two branches: the anterior tibial vein and the connecting branch. The anterior (medial) tibial vein becomes the main deep draining vein of the calf. The anterior tibial vein and primitive fibular veins together now constitute the sciatic vein, which is the second embryonic vein. A part of the primitive fibular vein distal to the anterior tibial vein/branch evolutes to become the short/lesser saphenous vein.

Third phase: femoral vein with persisting sciatic vein A connecting branch growing medially from the middle of the sciatic vein connects with a new proximal medial vessel that will become the femoral vein and the definitive deep venous system, while the sciatic vein regresses. A third embryonic vein of the leg develops to become the femoral vein, which terminates in the posterior cardinal vein, anterior to the sciatic vein. This advances toward the connecting branch of the lateral fibular/sciatic vein. The femoral vein is further evoluted with anastomoses to sciatic veins and passes down the leg as the posterior tibial vein, to finish the evolution of the veins along the lower extremity. This third embryonic vein is also known as the precursor of the long/greater saphenous vein.

With a defect in the second stage, the lateral fibular vein will persist and become the marginal vein. However, if a defect occurs in the passage to the third stage, a sciatic vein will remain as the main draining vein of the limb. As an embryonic vein, a persisting marginal vein is always valveless and can cause a severe reflux resulting in chronic venous hypertension/stasis as well as a high risk of venous thrombosis and subsequent pulmonary embolism among Klippel-Trenaunay syndrome patients.76,77

The venous development of the upper extremities is almost identical to that of the lower extremities.74,75 The ulnar portion of the border/marginal vein persists, forming the subclavian, axillary, and basilic veins at different levels. The subclavian vein eventually drains into the anterior cardinal vein, which subsequently evolutes to the internal jugular vein. The cephalic vein develops secondarily in relationship to the radial border vein, and it later anastomoses with the external jugular vein and finally opens into the axillary vein.

REFERENCES 1. Lee BB, Villavicencio L, Kim YW, et al. Primary Budd-Chiari syndrome: outcome of endovascular management for suprahepatic venous obstruction. J Vasc Surg. 2006;43:101-108. 2. Romagnoli R, Bertolani M, Saviano M, Pantusa M, Modena MG, Benassi A. Developmental interruption of the intra-hepatic segment of the inferior vena cava with azygos-hemiazygos continuation. Eur J Radiol. 1984;4:244- 247. 3. Lee BB, Laredo J, Lee TS, Huh S, Neville R. Terminology and classification of congenital vascular malformations. Phlebology. 2007;22:249-252. 4. Lee BB, Villavicencio L. General considerations. Congenital vascular malformations. Arteriovenous anomalies. In: Cronenwett JL, Johnston KW, eds. Rutherfords Vascular Surgery. 7th Edition. Philadelphia, PA, USA: Saunders Elsevier;2010:1046-1064. 5. Zamboni P, Galeotti R, Menegatti E, et al. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis J Neurol Neurosurg Psychiatry. 2009;80:392-399. 6. Lee BB, Laredo J, Neville R. Embryological background of truncular venous malformation in the extracranial venous pathways as the cause of chronic cerebrospinal venous insufficiency. Int Angiol. 2010;29:95- 108. 7. Leu HJ. Pathoanatomy of congenital vascular malformations. In: Belov S, Loose DA, Weber J, eds. Vascular Malformations. Reinbek, Germany: Einhorn-Presse Verlag;1989;16:37-46. 8. Woolard HH. The development of the principal arterial stems in the forelimb of the pig. Contrib Embryol. 1922;14:139-154. 9. Lee BB. New approaches to the treatment of congenital vascular malformations (CVMs) single center experiences (Editorial Review). Eur J Vasc Endovasc Surg. 2005;30:184-197. 10. Bastide G, Lefebvre D. Anatomy and organogenesis and vascular malformations. In: Belov St, Loose DA, Weber J, eds. Vascular Malformations. Reinbek: Einhorn-Presse Verlag GmbH;1989:20-22. 11. Lee BB, Bergan JJ. Advanced management of congenital vascular malformations: a multidisciplinary approach. Cardiovasc Surg. 2002;10:523-533. 12. Lee BB, Laredo J, Deaton DH, et al. Arteriovenous malformations: evaluation and treatment. In: Gloviczki P, ed. Handbook of Venous Disorders. Guidelines of the American Venous Forum. 3rd Edition. London, UK: A Hodder Arnold Ltd;2009. 13. Lee BB, Do YS, Byun HS, Choo IW, Kim DI, Huh SH. Advanced management of venous malformation with ethanol sclerotherapy: mid-term results. J Vasc Surg. 2003;37:533-538. 14. Lee BB. Current concept of venous malformation (VM). Phlebolymphology. 2003;43:197-203. 15. Lee BB, Kim YW, Seo JM, et al. Current concepts in lymphatic malformation (LM). J Vasc Endovasc Surg. 2005;39:67-81. 16. Lee BB, Villavicencio JL. Primary lymphedema and lymphatic malformation: are they the two sides of the same coin? Eur J Vasc Endovasc Surg. 2010;39:646-653. 17. Lee BB, Lardeo J, Neville R. Arteriovenous malformation: how much do we know? Phlebology. 2009;24:193- 200. 18. Lee BB, Do YS, Yakes W, Kim DI, Mattassi R, Hyon WS. Management of arterial-venous shunting malformations (AVM) by surgery and embolosclerotherapy. A multidisciplinary approach. J Vasc Surg. 2004;39:590-600. 19. Goldman MP, Fitzpatrick RE, Ruiz- Esparza J. Treatment of port-wine stains (capillary malformation) with the flashlamp-pumped pulsed dye laser. J Pediatr. 1993;122:71-77. 20. Berwald C, Salazard B, Bardot J, Casanova D, Magalon G. Port wine stains or capillary malformations: surgical treatment. Ann Chir Plast Esthet. 2006;51:369-372. 21. Lee BB, Laredo J, Lee SJ, Huh SH, Joe JH, Neville R. Congenital vascular malformations: general diagnostic principles. Phlebology. 2007;22:253-257. 22. Lee BB, Laredo J, Kim YW, Neville R. Congenital vascular malformations: general treatment principles. Phlebology. 2007;22:258-263. 23. Lee BB. Changing concept on vascular malformation: no longer enigma. Ann Vasc Dis. 2008;1:11-19. 24. Lee BB. Mastery of vascular and endovascular surgery. In: Zelenock, Huber, Messina, Lumsden, Moneta (eds). Chapter 76. Arteriovenous malformation. Philadelphia: Lippincott, Williams and Wilkins publishers;2006:597-607. 25. Belov S. Classification, terminology, and nosology of congenital vascular defects. In: Belov S, Loose DA, Weber J, eds. Vascular Malformations. Reinbek, Germany: Einhorn-Presse;1989:25-30. 26. Belov ST. Anatomopathological classification of congenital vascular defects. Sem Vasc Surg. 1993;6:219-224. 27. Zamboni P, Cossu A, Carpanese L, Simonetti G, Massarelli G, Liboni A. The so-called venous aneurysms. Phlebology. 1990;5:45-50. 28. Vaket L, Poppelier G, Vermeire P. Sur un cas danomalie combine de la veine cave suprieure et du systme azygos. Acta Anat. 1958 ;32:235-239. 29. Croquet V, Aube C, Pilette C, et al. Syndrome due to membranous obstruction of the inferior vena cava of congenital origin. Ten-year follow-up after radiologic treatment. Gastroenterol Clin Biol. 1999;23:259-263. 30. Rao KS, Gupta BK, Banerjee A, Srivastava KK. Chronic Budd-Chiari syndrome due to congenital membranous obstruction of the inferior vena cava: clinical experience. Aust N Z J Surg. 1989;59:335-338. 31. Kim YW, Lee BB, Cho JH, Do YS, Kim DI, Kim ES. Haemodynamic and clinical assessment of lateral marginal vein excision in patients with a predominantly venous malformation of the lower extremity. Eur J Vasc Endovasc Surg. 2007;33:122-127. 32. Mattassi R. Approach to marginal vein: current issue. Phlebology. 2007;22:283- 286. 33. Lee BB, Laredo J, Deaton D, et al. Endovascular management of Budd- Chiari Syndrome suprahepatic inferior vena cava occlusive disease. In: Heuser RR, Henry M, eds. Textbook of Peripheral Vascular Interventions. Second edition. Section XII. Chapter 83. London, UK: Informa Healthcare, Informa UK Ltd;2008:725-731 34. Zamboni P, Pisano L, Mari C, Galeotti R, Feo C, Liboni A. Membranous obstruction of the inferior vena cava and Budd-Chiari syndrome. Report of a case. J Cardiovasc Surg. 1996 (Torino); 37:583-587. 35. Abe T, Singer RJ, Marks MP, Norbash AM, Crowley RS, Steinberg GK. Coexistence of occult vascular malformations and developmental venous anomalies in the central nervous system: MR evaluation. Am J Neuroradiol. 1998;19:51-57. 36. Schaller B. Physiology of cerebral venous blood flow: from experimental data in animals to normal function in humans. Brain Res Rev. 2004;46:243- 260. 37. Schreiber SJ, Doepp F, Klingebiel R, Valdueza JM. Internal jugular vein valve incompetence and intracranial venous anatomy in transient global amnesia. J Neurol Neurosurg Psychiatry. 2005;76:509-513. 38. Akkawi NM, Agosti C, Rozzini L, Anzola GP, Padovani A. Transient global amnesia and disturbance of venous flow patterns. Lancet. 2001;357:957. 39. Lee BB, Bergan J. Gloviczki P, et al; International Union of Phlebology (IUP). Diagnosis and treatment of venous malformations Consensus Document of the International Union of Phlebology (IUP)-2009. Int Angiol. 2009;28:434-451. 40. Nedelmann M, Kaps M, Mueller-Forell W. Venous obstruction and jugular valve insufficiency in idiopathic intracranial hypertension. J Neurol. 2009;256:964-969. 41. Leriche H, Aubin ML, Aboulker J. Cavo-spinal phlebography in myelopathies. Stenoses of internal jugular and azygos veins, venous compressions and thrombosis. Acta Radiol Suppl. 1976;347:415-417. 42. Langman J. Medical Embryology. 5th ed. Baltimore, MD: Williams and Wilkins;1985:212217. 43. Warwick R, Williams P. Grays Anatomy. 37th ed. Edinburgh, London, Melbourne, New York: Churchill Livingstone;1989:326-327. 44. Hamilton WJ, Mossman HW. Hamilton, Boyd & Mossmans Human Embryology. 4th ed. Cambridge: Heffer;1972:261. 45. Collins P. Embryology and development. In: Williams PL, Bannister LH, Berry MM, et al (eds). Grays Anatomy: The Anatomical Basis of Medicine and Surgery. 38th ed. Edinburgh: Churchill Livingston;1995:327. 46. Padget DH. The development of the cranial venous system in man, from the viewpoint of comparative anatomy. Contrib Embryol Carneg Inst Washington. 1957;36:79-140. 47. Beattie J. The importance of anomalies of the superior vena cava in man. Canad Med Assoc J. 1931;25:281-284. 48. FitzGerald DP. The study of developmental abnormalities as an aid to that of human embryology, based on observations on a persistent left superior vena cava. Dublin J Med Sci. 1909;14-18. 49. Keyes DC, Keyes HC. A case of persistent left superior vena cava with reversed azygos system. Anat Rec. 1925;31:23-26. 50. Nandy K, Blair CB, Jr. Double superior vena cavae with completely paired azygos veins. Anat Rec. 1965;15:1-9. 51. Huffmire AP, Bower GC. A case of persistence of the left superior vena cava in an aged adult. Anat Rec. 1919- 20;17:127-129. 52. Basu BN. Persistent left superior vena cava, left duct of Cuvier and left horn of the sinus venosus. J Anat. 1932;66:628-270. 53. Greenfield WS. Persistence of the left vena cava superior, with absence of right. Trans Pathol Soc Lond. 1876;27:120-124. 54. Atwell WJ, Zoltowski P. A case of a left superior vena cava without a corresponding vessel on the right side. Anat Rec. 1938;70:525-532. 55. Howden R. Case of double superior vena cava with left -sided arrangement of the azygos vein. J Anat Physiol. 1887;21:72-75. 56. Gruber W. Duplicitt der vena cava superior, mit vorkommen zweir nenae azygae und einer sufficienten valvula an der mndung der vena azygos sinistra. Arch Pathol Anat Physiol Klin Med. 1880;81:462-465. 57. Krizan Z, Herman O, Dzidrov V. Teilweiser fortbestand des supracardinalsystems neben der normalen vena cava inferior beim menschen. Acta Anat. 1958;34:312- 325. 58. Lewis FT. The development of vena cava inferior. Am J Anat. 1902;1. 59. Bailey FR, Miller AM. Development of the vascular system. In: Textbook of Embryology. 2nd edition. New York: William Woon and Company;1911:222-291. 60. Nemec J, Heifetz S. Persistence of left supracardinal vein in an adult patient with heart-hand syndrome and cardiac pacemaker. Congenit Heart Dis. 2008;3:219-222. 61. McClure CFW, Butler EG. The development of the vena cava inferior in man. Am J Anat. 1925:35:331-383. 62. Cornillie P, Van Den Broeck W, Simoens P. Origin of the infrarenal part of the caudal vena cava in the pig. Anat Histol Embryol. 2008;37:387-393. 63. Nemec J, Heifetz S. Persistence of left supracardinal vein in an adult patient with heart-hand syndrome and cardiac pacemaker. Congenit Heart Dis. 2008;3:219-222. 64. Hashmi ZA, Smaroff GG. Dual inferior vena cava: two inferior vena cava filters. Ann Thorac Surg. 2007;84:661- 663. 65. Esposito S, Mansueto G, Amodio F, et al. Duplication of the vena cava inferior with a continuation into the vena azygos. A report of a rare case. Minerva Chir. 1999;54:261-265. 66. Munechika H, Cohan RH, Baker ME, Cooper CJ, Dunnick NR. Hemiazygos continuation of a left inferior vena cava: CT appearance. J Comput Assist Tomogr. 1988;12:328-330. 67. Honma S, Tokiyoshi A, Kawai K, Koizumi M, Kodama K. Left inferior vena cava with regressed right inferior vena cava. Anat Sci Int. 2008;83:173- 178. 68. Gil RJ, Prez AM, Arias JB, Pascual FB, Romero ES. Agenesis of the inferior vena cava associated with lower extremities and pelvic venous thrombosis. J Vasc Surg. 2006;44:1114- 1116. 69. Romagnoli R, Bertolani M, Saviano M, Pantusa M, Modena MG, Benassi A. Developmental interruption of the intra-hepatic segment of the inferior vena cava with azygos-hemiazygos continuation. Eur J Radiol. 1984;4:244- 247. 70. Trigaux JP, Vandroogenbroek S, De Wispelaere JF, Lacrosse M, Jamart J. Congenital anomalies of the inferior vena cava and left renal vein: evaluation with spiral CT. J Vasc Interv Radiol. 1998;9:339-345. 71. Royal SA, Callen PW. CT evaluation of anomalies of the inferior vena cava and left renal vein. AJR Am J Roentgenol. 1979;132:759-763. 72. Walden R, Hiss J, Morag B, Adar R. Congenital membranous obstruction of the inferior vena cava. Isr J Med Sci. 1978;14:342-346. 73. Wang ZG, Zhu Y, Wang SH, et al. Recognition and management of Budd-Chiari syndrome: report of one hundred cases. J Vasc Surg. 1989;10:149-156. 74. Lewis FT. The development of the veins in the limbs of rabbit embryo. Am J Anat. 1905;5:1-120. 75. Wyman J. On symmetry and homology in. limbs. Proc Boston Soc Nat Hist. 1867;11:246-278. 76. Gloviczki P, Stanson AW, Stickler GB, et al. Trenaunay syndrome: the risks and benefits of vascular interventions. Surgery. 1991;110:469-479. 77. Noel AA, Gloviczki P, Cherry KJ Jr, Rooke TW, Stanson AW, Driscoll DJ et al. Surgical treatment of venous malformations in Klippel-Trenaunay syndrome. J Vasc Surg. 2000;32:840- 847.

See original here:
Venous embryology: the key to understanding anomalous ...